Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Change in Receivables (2022 - 2025)

Historic Change in Receivables for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $379002.0.

  • 60 Degrees Pharmaceuticals' Change in Receivables rose 128059.89% to $379002.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $350214.0, marking a year-over-year increase of 8847.66%. This contributed to the annual value of $255416.0 for FY2024, which is 3778.94% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Change in Receivables stood at $379002.0 for Q3 2025, which was up 128059.89% from -$193209.0 recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year Change in Receivables high stood at $379002.0 for Q3 2025, and its period low was -$193209.0 during Q2 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Change in Receivables value was $36890.0 (recorded in 2023), while the average stood at $47977.2.
  • The largest annual percentage gain for 60 Degrees Pharmaceuticals' Change in Receivables in the last 5 years was 128059.89% (2025), contrasted with its biggest fall of 87334.51% (2025).
  • 60 Degrees Pharmaceuticals' Change in Receivables (Quarter) stood at -$149076.0 in 2022, then surged by 162.6% to $93323.0 in 2023, then surged by 74.58% to $162926.0 in 2024, then skyrocketed by 132.62% to $379002.0 in 2025.
  • Its Change in Receivables stands at $379002.0 for Q3 2025, versus -$193209.0 for Q2 2025 and $1495.0 for Q1 2025.